Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Piero Chiodi is active.

Publication


Featured researches published by Piero Chiodi.


Experimental Gerontology | 1990

Levels of carnitines in brain and other tissues of rats of different ages: effect of acetyl-L-carnitine administration.

Franco Maccari; Attilio Arseni; Piero Chiodi; M.Teresa Ramacci; Luciano Angelucci

Male Sprague-Dawley rats, aged 2, 5, 16, 20 and 30 months and normally fed, were used for determination of carnitines in the brain, serum, heart, tibial muscle, liver and urine. With respect to 5-month-old animals, those aged 30 months exhibited a statistically significant decrement of total carnitine levels in the brain, serum, heart and tibial muscle, accompanied by a dramatic increment in the liver. This suggests impaired net transport of carnitines from the liver to the blood in old age. Urinary excretion was similar in the two age groups. One group received from 5 months on daily 75 mg/kg acetyl-L-carnitine in drinking water. At 20 months, the treated animals showed levels of brain, heart and serum carnitines similar to those of 5-month-old animals. The recovery of brain, heart and serum carnitines in the old animals treated with acetyl-L-carnitine indicates that intestinal absorption and tissue uptake remain sufficiently efficient in the course of aging. The lower level of brain lipofuscins due to acetyl-L-carnitine treatment may be related to the effect of the compound on acetylcholine metabolism.


Journal of Medicinal Chemistry | 2001

Reversible Carnitine Palmitoyltransferase Inhibitors with Broad Chemical Diversity as Potential Antidiabetic Agents

Fabio Giannessi; Piero Chiodi; Mauro Marzi; Patrizia Minetti; Pompeo Pessotto; Francesco De Angelis; Emanuela Tassoni; Roberto Conti; Fabrizio Giorgi; Massimo Mabilia; Natalina Dell'uomo; Sandra Muck; Maria Ornella Tinti; Paolo Carminati; Arduino Arduini

A series of carnitine related compounds of general formula XCH(2)CHZRCH(2)Y were evaluated as CPT I inhibitors in intact rat liver (L-CPT I) and heart mitochondria (M-CPT I). Derivative 27 (ZR = -HNSO(2)R, R = C(12), X = trimethylammonium, Y = carboxylate, (R) form) showed the highest activity (IC(50) = 0.7 microM) along with a good selectivity (M-CPT I/L-CPTI IC(50) ratio = 4.86). Diabetic db/db mice treated orally with 27 showed a significant reduction of serum glucose levels.


Lipids | 1987

L-carnitine effect on plasma lipoproteins of hyperlipidemic fat-loaded rats

Franco Maccari; A. Arseni; Piero Chiodi; Maria Teresa Ramacci; Luciano Angelucci; W. C. Hulsmann

The effect of oral L-carnitine administration to rats fed olive oil has been studied. Carnitine significantly decreased triglyceride, cholesterol and phospholipid levels. Particularly, the levels of chylomicron and very low density lipoproteins in the blood were lowered. Low density lipoprotein levels were not affected, and high density lipoproteins were found to be decreased by 20%. Because carnitine did not change the composition of chylomicron and very low density lipoproteins fraction or affect the gastrointestinal triglyceride residue (about 1/3 of the original load), an effect of carnitine on hepatic fatty acid handling is most likely. The lowering of plasma free fatty acid levels by carnitine administration is in favor of an effect of carnitine on fatty acid handling. The effect on the liver is illustrated by the study of acetoacetate formation in in vitro perfused livers from previously olive oil loaded±carnitine-treated rats. Carnitine pretreatment stimulated ketogenesis. It is speculated that carnitine administration, by promoting β-oxidation, lowers the production of very low density lipoproteins. This may be accomplished partly by an increase in the hepatic level of fatty acid binding protein, which also has been observed.


International Journal of Biochemistry | 1994

Carnitine and derivatives in the central nervous system of chick embryo

Piero Chiodi; B. Clani; Susan Kentroti; Franco Maccari; Antonia Vernadakis; Luciano Angelucci; Maria Teresa Ramacci

1. Carnitine contents and the activity of carnitine acetyltransferase in the egg, in the embryo, and in different brain areas of central nervous system in chick embryo were determined in the course of development. 2. The egg showed low levels of free carnitine and acetylcarnitine. 3. In the whole embryo, at first stages of development, long chain acylcarnitine and acetylcarnitine were the best represented classes of carnitines. 4. In the brain regions acetylcarnitine levels, high at the first days, showed a continual decrease during development. 5. The activity of carnitine acetyltransferase increased and was totally related to development.


Biochimica et Biophysica Acta | 1992

Tissue lipid accumulation by l-aminocarnitine, an inhibitor of carnitine-palmitoyltransferase-2. Studies in intact rats and isolated mitochondria

Piero Chiodi; Franco Maccari; Maria Teresa Ramacci

Tissues of fasted animals treated with L-aminocarnitine (L-3-amino-4-trimethylaminobutyrate) showed an accumulation of long-chain acylcarnitines and triacylglycerols. Blood levels of free fatty acids, long-chain acylcarnitines and triacylglycerol-rich lipoproteins were found to be increased, whereas glucose was reduced. The liver mitochondria isolated from rats treated with L-aminocarnitine utilized both pyruvate and succinate normally, but were not able to oxidize palmitoylcarnitine. In vitro oxidation of palmitoylcarnitine by liver mitochondria was inhibited by L-aminocarnitine in a concentration-dependent fashion in contrast to succinate and pyruvate oxidation which was not modified. L-aminocarnitine proved to be a potent and selective inhibitor (IC50 = 805 nM) of the carnitine palmitoyltransferase isoenzyme, located on the inner side of the mitochondrial inner membrane (CPT2). The activity of the carnitine palmitoyltransferase isoenzyme located on the mitochondrial outer membrane inhibitable by malonyl-CoA (IC50 = 19 microM), was not inhibited by 0.8 microM L-aminocarnitine. Both in vitro and in vivo effects of L-aminocarnitine suggest that the substance has a specific and potent inhibitory action on CPT2. Its in vivo inhibition results in a dramatic increase of long-chain acylcarnitines in various organs, that it is why this increase can be considered a very good marker of CPT2 inhibition. A markedly altered lipid metabolism was observed.


Basic Research in Cardiology | 1987

The effect of exogenous L-carnitine on biochemical parameters in serum and in heart of the hyperlipidaemic rat

Franco Maccari; A. Arseni; Piero Chiodi; Maria Teresa Ramacci; Luciano Angelucci

In previous experiments we have demonstrated that L-carnitine administration is capable of reducing olive oil-induced lipidaemia in the rat. In the present study we determined the effect of L-carnitine on the levels of (acyl)carnitines in heart and serum in addition to its effect on serum levels of lipids and ketone bodies after olive oil gavage feeding. L-carnitine was found to reduce the level of myocardial long-chain acylcarnitine which was increased by the olive oil treatment. It also increased the levels of carnitine and acid soluble acylarnitines in both heart and serum. L-carnitine administration caused a clearcut decrease of olive oil-induced lipidaemia and ketonaemia. These effects of added L-carnitine strongly suggest that the stimulation of the beta-oxidation in the mitochondria (at the expense of extra mitochondrial triglycerceride synthesis) is suboptimal after fat loading.


Archive | 2000

QSAR of a Series of Carnitine Acetyl Transferase (CAT) Substrates

Grazia Gallo; M. Mabilia; Mose Santaniello; Maria Ornella Tinti; Piero Chiodi

Carnitine acyl transferases are a family of enzymes that differ with respect to subcellular localization and substrate specificity. Carnitine acetyl transferase (CAT) is mainly found in the mitochondrial matrix where it is postulated to play a key role in stabilizing the CoA-SH/CoA-SAc ratio.1 CAT catalyses the reversible reaction: n n


Journal of Medicinal Chemistry | 2003

Discovery of a long-chain carbamoyl aminocarnitine derivative, a reversible carnitine palmitoyltransferase inhibitor with antiketotic and antidiabetic activity.

Fabio Giannessi; Pompeo Pessotto; Emanuela Tassoni; Piero Chiodi; Roberto Conti; Francesco De Angelis; Natalina Dell'uomo; Roberto Catini; Roberto Deias; Maria Ornella Tinti; Paolo Carminati; Arduino Arduini


Archive | 1999

Compounds having reversible inhibiting activity of carnitine palmitoyl-transferase

Fabio Giannessi; Mauro Marzi; Patrizia Minetti; Francesco De Angelis; Maria Ornella Tinti; Piero Chiodi; Arduino Arduini

Acetyl - L - carnitine + Coa - SH leftrightarrow L - carnitine + acetyl - Coa


Journal of The Peripheral Nervous System | 1996

L-carnitine and acetyl-L-carnitine in human nerves from normal and diabetic subjects.

Elio Scarpini; Paola Doneda; Silvia Pizzul; Piero Chiodi; Maria Teresa Ramacci; Pierluigi Baron; Giancarlo Conti; Giorgio Sacilotto; Arduino Arduini; G. Scarlato

Collaboration


Dive into the Piero Chiodi's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Luciano Angelucci

Sapienza University of Rome

View shared research outputs
Researchain Logo
Decentralizing Knowledge